Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions

Recurrent Hepatocellular Cancer

Interventions

DRUG

toripalimab

240mg,ivgtt, every three weeks as a cycle, the first day of each cycle.

DRUG

Lenvatinib

12mg (weight ≥60kg) or 8mg (weight \<60kg) orally, once a day

DEVICE

Radiofrequency ablation

ultrasound-guided percutaneous radiofrequency ablation of recurrent hepatocellular carcinoma

All Listed Sponsors

lead

Henan Cancer Hospital

OTHER_GOV